Efficacy News and Research

RSS

Total formulation impacts a surface sanitizer's efficacy against norovirus, finds study

A new study by North Carolina State University, in partnership with GOJO, found that total formulation (the active ingredients and non-active ingredients) significantly impacts a surface sanitizer or disinfectant's efficacy against norovirus – the leading cause of foodborne illness in the United States.

13 Sep 2022

What is the effectiveness of tecovirimat for treatment of monkeypox?

Researchers assessed the effectiveness of tecovirimat in monkeypox treatment in a new study.

13 Sep 2022

Immunotherapy before surgery improves outcomes in many patients with stage II–IV cutaneous squamous cell carcinoma

In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center, 63.3% of patients with stage II–IV cutaneous squamous cell carcinoma (CSCC) saw their tumors nearly or completely disappear when treated with immunotherapy before surgery.

13 Sep 2022

$Fruquintinib provides survival benefits for patients with refractory metastatic colorectal cancer$

Fruquintinib provides survival benefits for patients with refractory metastatic colorectal cancer

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.

13 Sep 2022

How effective is vitamin D supplementation in COVID-19?

The current paper addresses the considerable evidence now supporting the efficacy of vitamin D in COVID-19, as well as its safety.

13 Sep 2022

Forecasting COVID-19 surges based on SARS-CoV-2 mutation surveillance

Researchers predicted surges in SARS-CoV-2 infections based on alterations in SARS-CoV-2 mutations.

13 Sep 2022

MSK researchers reveal a promising treatment option for bladder cancer patients

Researchers from Memorial Sloan Kettering Cancer Center (MSK) shared a promising treatment option for bladder cancer patients today at The European Society for Medical Oncology (ESMO) Congress 2022.

13 Sep 2022

Study investigates the efficacy and safety of selpercatinib in a diverse group of patients

The highly selective RET inhibitor selpercatinib was well-tolerated and achieved durable objective responses across multiple tumor types in the Phase I/II LIBRETTO-001 trial, according to researchers from The University of Texas MD Anderson Cancer Center.

13 Sep 2022

The impact of the infant gut microbiome on vaccine efficacy

A new study reports the effect of the infant gut microbiome on vaccine efficacy.

13 Sep 2022

Mucosal vaccination triggers superior T cell response against SARS-CoV-2 variants

In a recent study posted to the bioRxiv* server, researchers in Singapore and the United States demonstrated that intranasal (I.N.) delivery of a mucosal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination triggered a superior T cell response compared to an equivalent dose of antigen delivered by the subcutaneous (S.C.) route.

12 Sep 2022

N-dihydrogalactochitosan shows promise as a mucosal vaccine adjuvant against SARS-CoV-2

In a recent study posted to the bioRxiv* server, researchers in the United States demonstrated the efficacy of a novel biopolymer, N-dihydrogalactochitosan (GC), as an adjuvant for next-generation mucosal coronavirus disease 2019 (COVID-19) vaccine.

12 Sep 2022

Are antibodies induced by historic smallpox vaccination cross-reactive with the monkeypox virus?

esearchers measured the monkeypox virus-neutralizing antibodies produced by the vaccinia virus vaccine, modified vaccinia virus Ankara vaccine, and monkeypox virus to understand the efficacy of the MVA-Bavarian Nordic vaccine currently being used against monkeypox.

12 Sep 2022

Small molecule inhibitor found to be effective against SARS-CoV-2 variants

In a new study, researchers developed RK-33, a small molecule inhibitor of DDX3, and evaluated its efficacy against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs).

12 Sep 2022

BNT162b2 SARS-CoV-2 vaccinations found to reduce incidence of long COVID symptoms

Researchers assessed the association between Pfizer-BioNTech’s SARS-CoV-2 BNT162b2 messenger ribonucleic acid (mRNA) vaccination and the incidence of post-COVID-19 symptoms among Israeli adults.

12 Sep 2022

Did the US jump the gun with the new omicron-targeted vaccines?

Last month, the FDA authorized omicron-specific vaccines, accompanied by breathless science-by-press release and a media blitz.

12 Sep 2022

Dissecting vaccinia virus and monkeypox virus-specific T cell responses in humans

In a new study, a team of researchers studied different antigens targeted by vaccinia virus (VACV)- and monkeypox virus (MPXV)-specific T cells.

12 Sep 2022

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

In a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).

12 Sep 2022

Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infection

In a recent study posted to the bioRxiv* preprint server, researchers in Germany and the United Kingdom investigated the interferon responses induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant and SARS-CoV-2 Omicron sub-variants BA.1 and BA.5, and their efficacy in protecting cells from influenza A virus super-infection.

12 Sep 2022

Study shortlists potential drug repurposing candidates to treat symptoms in ASD

Can you teach an old drug new tricks? Although drug treatments for the core symptoms of autism spectrum disorder (ASD) are not currently available, could an existing drug provide a new treatment, even if it previously had no association with ASD? This was the question asked by a new study in the journal Frontiers in Pharmacology. The researchers used a computer model that encompasses proteins involved in ASD and the way they interact.

12 Sep 2022

Vaccinia virus-based vaccines mount a robust immune response against the monkeypox virus

New research has suggested that recommended vaccinia virus (VACV)-based vaccines will mount a robust immune response against the monkeypox virus observed in the current outbreak (MPXV-2022).

12 Sep 2022

Efficacy News and Research

Total formulation impacts a surface sanitizer's efficacy against norovirus, finds study

What is the effectiveness of tecovirimat for treatment of monkeypox?

Immunotherapy before surgery improves outcomes in many patients with stage II–IV cutaneous squamous cell carcinoma

Fruquintinib provides survival benefits for patients with refractory metastatic colorectal cancer

How effective is vitamin D supplementation in COVID-19?

Forecasting COVID-19 surges based on SARS-CoV-2 mutation surveillance

MSK researchers reveal a promising treatment option for bladder cancer patients

Study investigates the efficacy and safety of selpercatinib in a diverse group of patients

The impact of the infant gut microbiome on vaccine efficacy

Mucosal vaccination triggers superior T cell response against SARS-CoV-2 variants

N-dihydrogalactochitosan shows promise as a mucosal vaccine adjuvant against SARS-CoV-2

Are antibodies induced by historic smallpox vaccination cross-reactive with the monkeypox virus?

Small molecule inhibitor found to be effective against SARS-CoV-2 variants

BNT162b2 SARS-CoV-2 vaccinations found to reduce incidence of long COVID symptoms

Did the US jump the gun with the new omicron-targeted vaccines?

Dissecting vaccinia virus and monkeypox virus-specific T cell responses in humans

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

Interferon response induced by Omicron BA.1 and BA.5 prevents influenza A infection

Study shortlists potential drug repurposing candidates to treat symptoms in ASD

Vaccinia virus-based vaccines mount a robust immune response against the monkeypox virus

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News